Clinical trials of some important immunotherapeutic drugs
thrive, cancers
CERVICAL CANCER, CANCERS
Based on the current status of immunotherapies in cervical cancer, clinical trials of some important immunotherapeutic drugs were summarized and analyzed (The significant bispecific antibodies and their correspondingly selected clinical trials.As the firstly approved anti-PD-1 ICB, there were 33 clinical trials related to Pembrolizumab, including 21 in phase II, 19 in Phase II, and just 1 in phase III. 22 clinical trials of Pembrolizumab began after 2019 (including 2019), and in 2022 the number reached the top with nine trials. There were 11 trials concerned with Nivolumab, all of which were phase I and/or phase II trials, as monotherapy or combined with other agents. Nivolumab is often combined with anti-CTLA-4 antibody ipilimumab, not only for recurrent/metastatic cervical cancer in the classical CheckMate 358 (NCT02488759) but also for locally advanced cervical cancer when combined with chemoradiotherapy. For Cemiplimab (anti-PD-1), a phase III trial in conjunction with vaccine therapy showed its result. HLX 10 is mainly used in combination with chemotherapy, and one trial has obtained its result at present. There are six clinical trials using Sintilimab, which are all phase II (one phase I/II). And only one phase II trial in combination with Anlotinib showed its results. Four clinical trials were related to Balstilimab, among which one had results. But one trial had been withdrawn, and one had been terminated.The advances of PD-L1 lag behind that of PD-1 in the treatment of advanced cervical cancer. The representative drug Atezolizumab has been studied in 20 clinical trials, which were mainly at the phase II stage, with three trials at the phase III stage.Bispecific antibodies have continued to thrive in recent years. As the approved bispecific antibody, there are six clinical trials related to AK104, including four phase II trials and two phase III trials. And they all started after 2020. The two phase III trials (one for locally advanced cervical cancer, and the other for recurrent/metastatic cervical cancer) demonstrate the urgent need for improvement in the treatment of both types of cervical cancer. For Bintrafusp Alfa (M7824, anti-PD-L1, and TGF-β), there are seven clinical trials (two phase I, one phase I/II, three phase II, and one phase III). The phase I/II trial of HPV vaccine PRGN-2009 alone or in combination with M7824 in HPV -associated cancers (NCT04432597) had shown its results. Another similar bispecific antibody SHR-1701 (anti-PD-L1 and TGF-β) also showed its preliminary result. And there is an ongoing phase III trial of SHR-1701 combined with platinum-containing chemotherapy as the first-line treatment.